Table 1: Cases hospitalized with RSV who previously qualified for palivizumab and were excluded according to 2014 guidance: Pre versus Post 2014 guidance adoption.
| Pre 2014 Guidance 2013/14 RSV Season (n = 10) N(%) or Median (IQR) |
Post 2014 Guidance 2014/15 and 2015/16 RSV Seasons (n = 16) N(%) or Median (IQR) |
P-value | |
|---|---|---|---|
| Sex (% males) | 70% (7) | 25% (4) | 0.064 |
| Previously healthy | 70% (7) | 62.5% (10) | 1.0000 |
| Premature (< 37 weeks) | 80% (8) | 87.5% (14) | 0.625 |
| Age (median months) | 3.78 (IQR 1.8-8.16) | 3.48 (IQR 1.62-6.27) | 0.732 |
| Length of stay (median days) | 3 (IQR 1.25-5.75) | 4 (IQR 2.65-9) | 0.205 |
| CLD | 10% (1) | 6% (1) | 1.00 |
| CHD | 10% (1) | 6% (1) | 1.000 |
| Concurrent bacterial pneumonia | 0 | 19% (3) | 0.262 |
| Palivizumab for current season | 40% (4) | 6% (1) | 0.107 |
| Admission to higher level of care (ICU/IMC) | 50% (5) | 62.5% (10) | 0.689 |
| Oxygen requirement > 2 L | 50% (5) | 62.5% (10) | 0.689 |
| Mechanical ventilation | 20% (2) | 25% (4) | 1.000 |